key: cord-0426645-mfvrmxr3
authors: Rosenfeld, G.; Gabrielian, A.; Meyer, A.; Rosenthal, A.
title: Radiologist observations of chest X-rays (CXR) predict sputum smear microscopy status in TB Portals, a real-world database of tuberculosis (TB) cases
date: 2022-04-22
journal: nan
DOI: 10.1101/2022.04.21.22273975
sha: b95c4c406fbe0289f6c108b45a34b24fef3a6091
doc_id: 426645
cord_uid: mfvrmxr3

The Tuberculosis (TB) Portals is an international program of 14 countries connecting clinical, genomic, and radiologist specialists to develop an openly available repository of deidentified TB cases with multi-modal data such as case clinical characteristics, pathogen genomics, and radiomics. This real-world data resource contains over 4000 TB cases, principally drug resistant cases, with over 4000 chest X-rays (CXR) images. The scope of curated data offers a case-focused perspective into the drivers of disease incorporating the chronological context of the presented CXR data. Here, we analyze a cohort consisting of new TB cases to understand the relationship between baseline sputum microscopy status and nearby Chest X rays images. The Timika score, a lung biomarker of disease severity, was derived for each CXR using available radiologist observations. The Timika score along with the radiologist observations were compared for predictive performance of baseline sputum microscopy status. Baseline sputum microscopy status is a useful marker of pre-treatment disease severity and infectiousness. The modeling results support that both the radiologist observations as well as Timika score are predictive of smear status and that Timika score performs similarly to the top 5 radiologist features by feature selection. Moreover, inferential statistical analysis identifies the factors having the greatest association with sputum smear positivity such as presence of radiologist observations in both lungs, presence of cavity, presence of nodule, and Timika score itself. The results are consistent with prior reports showing Timika Score utility for predicting baseline sputum smear and disease status. We report testing of Timika Score on the largest, openly available real-world dataset of TB cases that can serve as a reference to explore extant and new TB disease severity scores bridging radiological, microbiological, and clinical data. To illustrate, we visualize Timika score from images in our database with other cases characteristics demonstrating that this score captures lung biomarker status consistent with known clinical risk factors.

Tuberculosis (TB) remains a major global pandemic with approximately 10 million new 49 cases and 1.5 million deaths each year (1, 2). With the emergence of the SARS-Cov2 global 50 pandemic in 2020, it is estimated that the TB pandemic may have worsened due to additional 51 strains and challenges encountered via healthcare systems around the world (3, 4). Concurrent to 52 those unfortunate events, drug resistant TB continues to be a persistent threat with up to ~20% of 53 TB isolates around the world estimated to be resistant to a major drug. Transmission of drug 54 resistant TB is an emerging phenomenon closely monitored by health authorities worldwide (5). 55

Drug resistant TB cases (DR-TB) are associated with poorer outcomes and more expensive cost 56 of care when compared to drug sensitive TB. DR-TB has a lower treatment success of 57 approximately 55% globally and Multi-or Extensively DR-TB care can cost up to 25 times that 58 of TB cases that are drug sensitive (6, 7). Therefore, real-world databases focusing on these DR 59 cases that span multi-domain case information are essential to identify novel relationships and 60 aspects of drug resistance to enable translational medicine to timely and efficiently address drug 61 resistance. 62

To eradicate TB, clinicians need rapid diagnostics of disease along with efficient means 63 of monitoring treatment response and completeness at discharge. Sputum smear microscopy has 64 been a primary method for diagnosis of pulmonary tuberculosis in low and middle income results from specimens prior to or on the treatment start date were selected. Those cases where 137 the specimen collection date was within 14 days of a CXR were included. For cases where 138 multiple pairs of specimens and CXRs existed, the last specimen prior to treatment was used. 139

For cases where multiple microscopy test results were present for a specimen, the last 140 microscopy test result for that specimen was used. For cases where multiple images existed, the 141 last imaging date was used. Unknown or non-standard microscopy results such as "Unknown 142 data" and "Saliva" were excluded. Code used for generating the cohort is provided in the Data 143 availability and code section. Ultimately, 572 new cases were selected from the database with 144 sputum microscopy results of Negative, 1 to 9 in 100 (1-9/100), 10 to 99 in 100 (1+), 1 to 9 in 1 145 (2+), 10 to 99 in 1 (3+), and More than 99 in 1 (4+) consisting of 259, 29, 144, 60, 58, and 22 146 cases respectively within this cohort. The cohort characteristics summarizing case details for the 147 sputum prediction cohort can be found in Supplementary Table 1 Table 3 . 179 MLR3 framework was used to define a set of prediction tasks as well as pipelines for 180 in the validation dataset to ascertain performance on data which has never been used during 206 model training. To compare performance of the top radiologist observations and Timika Score, 207 the best pipelines using the top radiologist derived features were compared by bootstrapping 208 without replacement (N = 200) to the best pipelines using Timika Score alone, or a featureless 209 pipeline as a control to indicate the density of observed model performance particular to this 210 dataset that may be due to random chance. 211

Calculation of inferential statistics 212 To estimate the univariate Odds Ratios (OR) and multivariate adjusted Odds Ratios 213 (AOR), the finalfit R package was used. Both_hugenodule1 feature was removed from the 214 analysis as it did not show any variance. As Timika Score is highly correlated with other 215 variables in the dataset (e.g. overall abnormal volume and cavity), MRMR feature selection 216 (https://mlr3filters.mlr-org.com/reference/mlr_filters_mrmr.html) was performed for the top 5 217 features to include in the multivariate modeling. As both_hugenodule1 feature was excluded, less 218 than 5 features were selected in the multivariate modeling. The both_lungs feature was included 219 in the multivariate model to adjust for indication of involvement of both lungs from sextant level 220 features when assessing estimated odds of sputum positivity. 221

Timika Score calculated and plotted using ggplot2 to visualize associations with other case 227 attributes. 228

For calculating temporal changes in Timika Score, those cases with an initial CXR 229 identified above were filtered for cases with an additional follow up CXR with radiologist 230 observation. The log2 transformed relative change were calculated for each image's Timika 231

Score comparing the earliest score with all subsequent scores. To account for differences in the 232 length of time between images that may impact the relative score change, the difference in 233 number of days between CXRs was calculated and the log2 transformed relative changes were 234 divided by the number of days between pairs of images for each case to generate the log2 235 relative change by day. 236

Data availability and code 237 The TB portals program necessitates all users of the data sign a DUA before access to the 238 underlying, de-identified clinical data is provided and the data can be requested at the following 239 URL (https://tbportals.niaid.nih.gov/download-data). Therefore, this study provides the code to 240 reproduce the analysis without the underlying raw data 241 (https://github.com/niaid/tbportals.xray.sputum.2021) in compliance with the DUA. To rerun the 242 analysis, interested parties can request data access by completing the DUA and then place the 243 downloaded files to the subdirectory of the data folder as provided in the GitHub repo 244 instructions. To aid reproducibility, the list of patient IDs and condition IDs used from the 245 sputum prediction analysis are provided in Supplementary Table 4 . The specific record 246 between Timika score and case characteristics of interest that are consistent with our prior 270 knowledge of TB clinical risk. 271

For instance, Timika Score of the initial image gradually increases with age of onset until 272 the relationship plateaus around age 50 and decreases although some of the decrease and initial 273 increase can likely be attributed to the lower density of observations at the two extremes of age 274 ( Fig 1A) . Timika Score decreases with increasing BMI until it plateaus around a BMI of ~25 275 ( Fig 1B) . Like age, the extremes of the BMI visualization need to be interpreted cautiously 276

given the lower densities. XDR cases, resistant to the most TB drugs and with the worst 277 outcomes, are observed to have a higher median Timika Score and interquartile range compared 278 to other case resistance types ( Fig 1C) . New This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. For instance, the log2 transformed change in Timika Score by day steadily decreases with 320 age of onset such that younger age shows greater relative change whereas older age shows less 321 relative change (Fig 2A) . Conversely, log2 transformed change in Timika Score by day 322 increases as BMI increases (Fig 2B) . Lower BMI demonstrates a smaller relative change as 323 compared to higher BMI. When examining relative change by resistance type of the case, Drug 324 sensitive cases are observed to have a larger relative change compared to drug resistant types 325 ( Fig 2C) . Similarly, new cases of TB show greater relative change compared to other types of 326 cases such as Prior treatment failure, Prior lost to follow up, Relapse, or Other prior status at the 327 start of the case (Fig 2D) . Visualizing by case outcomes demonstrates that undesirable outcomes 328 such as Died, Treatment failure, or Lost to follow up show decreased relative change by day 329 compared to beneficial outcomes such as Treatment completion or Cured (Fig 2E) To aid in visualizing the trendline, the y axis was limited to between -0.1 and 0.1 resulting in an 340 additional 9 outliers being removed for age of onset and BMI case numbers above respectively. 341

For C), D), and E), boxplots with interquartile range showing log2 relative change in Timika 342 Score by day compared by the type of drug resistance, status of case at start, and status of case at follow up, or Unknown show smaller relative changes compared to beneficial outcomes such as 363

Completed and Cured. As above for other visualizations, caution is warranted given the small 364 N's associated with certain subgroups. 365 366 Sputum smear microscopy results associate with Timika score in this cohort 367 of TB portals cases 368 We next assessed the previously reported role of Timika Score for predicting sputum 369 smear status by analyzing the selected cohort of new cases having microscopy results from 370 sputum specimens taken prior to treatment with associated images within two weeks of the 371 specimen (N = 572). Mean Timika Score is lowest amongst new cases with a sputum microscopy 372 result of negative and increases for microscopy results indicating a higher burden of bacteria 373 within sputum [1 to 9 in 100, 1+, 2+, etc.] (Fig 3) . Only the 4+ level shows slightly lower mean 374

Timika Score compared to the next highest level of 3+, which may be due to variance from the 375 lower number of available cases in this 4+ level (N = 22). This clear trend in the TB portals 376 dataset is consistent with previously reported role of Timika Score for predicting baseline 377 sputum status. 378 specimen taken prior to treatment start. Timika score is visualized by the smear microscopy 380 results of specimens taken prior to treatment start for which CXRs were available within two 381 weeks of specimen date (N = 572). Boxplots show median Timika Score for associated images 382 with interquartile range. Images associated with negative smear microscopy status have lower 383

Timika Scores while those with positive statuses (1 to 9 in 100, 1+, and higher) show 384

progressively higher Timika Scores that appear to plateau around 2+ or higher. The following 385 number of Timika Scores derived from radiologist observations of images are available for 386

Negative, 1 to 9 in 100 (1−9/100), 10 to 99 in 100 (1+), 1 to 9 in 1 (2+), 10 to 99 in 1 (3+), and 387 Inferential statistics associated with sputum microscopy status 390 Given the association of Timika Score with sputum smear microscopy, we continued our 391 investigation by assessing the risk of a positive sputum microscopy status (1 to 9 in 100, 1+, or 392 higher) compared to a negative status using Timika score along with the other derived features 393 from radiologist observations. To do so, we performed univariate and multivariate logistic 394 regression removing any feature with no variance that caused univariate or multivariate modeling 395 to fail. We leveraged MRMR feature selection to select the top 5 features for multivariate 396 models. Timika Score is derived from the radiological features (e.g., presence of cavity and 397 overall abnormal volume) so we wanted to select additional features that would not directly 398 correlate with Timika Score but still potentially correlate with sputum microscopy status. 399

We observe multiple features with evidence of involvement of both lungs showing higher 400 risk of sputum microscopy positivity including calcified nodules, fibrotic nodules, low density 401 nodules, involvement of both lungs by indication of any type of sextant feature, medium density 402 nodules, medium cavities, small cavities, multiple cavities, and small nodules (Table 1) This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022.

Odds ratios and adjusted odds ratios from univariate and multivariate logistic regression analysis 424 on derived features from radiologist observations of images taken within two weeks of 425 specimens prior to treatment start. Shown are the individual derived features from radiologist 426 observations along with the summary statistics across the prediction categories of Negative or 427

Positive (1 to 9 in 100, 1+, or higher sputum smear microscopy status Assessing predictive capacity of machine learning models 434 The TB portals offers a variety of radiologist observations of CXRs that may provide 435 additional information towards the prediction of baseline sputum smear microscopy status. 436 Therefore, we investigated the additional features comparing predictive performance to Timika 437 Score alone. By doing so, we sought to identify any additional features that might improve upon 438

Timika Score performance and to evaluate how well Timika Score itself could predict sputum 439 status when compared to various feature selection or dimensionality reduction techniques that 440 summarize the radiological features within the data. 441

for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 443 We noted that sputum smear scores of 2+ or greater showed a higher mean Timika Score 444 so we tried two predictive approaches: task one involved predicting positive (1 to 9 in 100, 1+, or 445 greater smear status indicating any active pathogen in the sputum) versus negative smear status 446 while task two involved predicting higher bacterial load positive (2+, 3+, or greater smear status) 447 versus negative sputum status. We split the data into a 70% training set and 30% validation set 448 for the model training and validation. All pipelines were created and run using the MLR3 449 package which allows for unbiased assessment of model performance by encapsulating the pre-450 processing steps within the cross-validation approach. All prediction tasks included featureless 451

pipelines showing a non-informative model that only predicts the most prevalent class or 452 randomly selects a class in case of a tie. Thus, the featureless model can be considered a control 453 and predictive models should perform significantly better than this featureless control model. 454

In the first prediction problem attempting to discriminate positive from negative status, 5-455 fold cross validation results on the training data showed that most models demonstrated 456 relatively similar predictive performance across pipelines (Table 2 ). Pipelines using top 5 457 components by principal component analysis (which captured ~ 50% of variability in the dataset) 458 tended to show slightly decreased performance in general. Since this prediction problem did not 459 have a large class imbalance, the addition of a class balancing step did not make a significant 460 impact to prediction performance for the pipelines tested. Of note, pipelines only including the 461 Timika Score showed equivalent performance in general to workflows using the top 5 predictive 462 features from various feature selection algorithms. There is a slight decrease in performance of 463 Timika-only models to the best top 5 feature selection model, which reflect that additional 464 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22273975 doi: medRxiv preprint features may provide some minimal improvement over Timika Score. To test predictive 465 performance on data which the models had not seen before, we trained the above models on the 466 entire training set and tested on 30% of held out validation data (Table 3) . We observed similar 467 findings to the cross-validated results we obtained from the training data. 468 Table 2 . Comparison of machine learning pipeline performance via 5-fold cross-validation 469

for predicting positive (1 to 9 in 100, 1+, or higher) versus negative sputum microscopy 470 status on training data. 471

. r a n g e r 0

.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 7  3  3  3  3  3  3  0  .  5  2  6  3  1  5  7  9 for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; s  c  a  l  e  .  f  l  t  .  m  r  m  r  .  c  l  a  s  s  i  f  .  n  a  i  v  e  _  b  a  y  e  s  0  .  6  5  7  8  9  4  7  -0  .  0  1  2  9  2  6  1  1  2   0  .  9  8  6  6  6  6  7  0  .  0  1  0  5  2  6  3  2   485 The machine learning pipeline is shown in the pipeline column. Model performance metrics 486

include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's 487

Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity 488 (classif.specificity). Each cell represents the metric for the performance on the 30% held-out 489 validation test set after training on the 70% training data. Pipelines using only the Timika Score 490

for prediction start with Timika in the pipeline name. Each pipeline shows all steps used in the 491 pipeline ending with the machine learning algorithm used and are ordered by classif.mcc. 492 493

We hypothesized that the second prediction task might demonstrate a performance boost 494 in predictive power since the 2+ sputum status or higher (very high pathogen load in the sputum) 495 showed a larger difference in Timika Score compared to negative. For this prediction task, we 496 removed the borderline 1 to 9 in 100 and 1+ sputum test results from the analysis. 5-fold cross 497 validation results on training set confirmed our hypothesis as we observed increases in 498 performance for reported metrics (Table 4) Score only workflows. In general, we observed equivalent performance from Timika Score only 500 pipelines to workflows using the top 5 predictive features from various feature selection 501 algorithms. The benchmarking suggests that while possible to achieve additional gains from the 502 set of derived radiologist observations, these would likely be minimal. Interestingly, though this 503 prediction problem shows a moderate class imbalance, the incorporation of class balancing did 504 not significantly increase or impair performance for the pipelines. When we tested models 505 trained on the entire training set on a validation set of 30% held out data, we saw similar 506 predictive performance to our observation of the 5-fold cross-validated results on the training set 507 (Table 5) . 508 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. for use under a CC0 license.

This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22273975 doi: medRxiv preprint

The machine learning pipeline is shown in the pipeline column. Model performance metrics 528

include Area under the curve (classif.auc), Balanced accuracy (classif.bacc), Matthew's 529

Correlation Coefficient (classif.mcc), Sensitivity (classif.sensitivity), and Specificity 530 (classif.specificity). Each cell represents the metric for the performance on the 30% held-out 531 validation test set after training on the 70% training data. Pipelines using only the Timika Score 532

for prediction start with Timika in the pipeline name. Each pipeline shows all steps used in the 533 pipeline ending with the machine learning algorithm used and are ordered by classif.mcc. 534 535

Comparison of best performing feature selection and Timika-only models by 536 bootstrapping 537 Though our initial training and validation testing suggested that Timika Score only 538 pipelines showed minimal differences with the top 5 feature models, we wanted to further test 539 this for statistical significance. We chose the best performing class-balanced pipelines from the 540 5-fold cross validated results obtained from the training data. Thus, the best top 5 feature 541 pipeline, Timika Score only pipeline, and a featureless pipeline were selected for further testing. 542

The featureless workflow is a control that would reveal the density of results expected due to 543 random chance regardless of any upstream preprocessing given that classes are balanced. We 544 perform a bootstrapping without replacement (N = 200) on the entire dataset using 70% of the 545 data for training and 30% for testing on each split. 546

The bootstrapping result on the prediction problem attempting to distinguish positive 547 from negative sputum results showed that the performance of the best top 5 feature pipeline was 548 slightly better than the Timika-only pipeline. Both showed significantly improved performance 549 from the workflow using a featureless model (Fig 4A) . The bootstrapping on the prediction 550 problem attempting to distinguish higher bacterial load sputum results (2+ or higher compared to 551 negative) did not show any difference in performance for the best Timika-only pipeline 552 compared to the best top 5 workflow ( Fig 4B) . As before, both pipelines performed significantly 553 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ; https://doi.org/10.1101/2022.04.21.22273975 doi: medRxiv preprint better than the workflow using the featureless model. These results are consistent with the idea 554 that Timika offers generally equivalent predictive performance to using the top 5 features from 555 the dataset. Inclusion of other features may offer minimal improvements in predictive 556 performance depending upon the model or set of features selected. 557 shown by the brackets. In A), the performance of the best pipelines for predicting positive (1 to 9 566 in 100, 1+, or higher) versus negative is shown whereas B) the performance of the best pipelines 567 for predicting high bacterial load positive (2+ or higher) versus negative is shown. Interestingly 568

there is a statistically significant difference between top 5 feature pipeline versus Timika Score 569 pipeline in A) and no significant difference in performance for Timika Score pipeline in B). This 570

shows that additional derived features from radiologist observations may result in small 571 performance gains although Timika Score alone provides generally equivalent prediction 572 performance for the identified best models. 573 574

Discussion 575 X ray imaging is a useful approach to diagnose and monitor disease progression and 576 status during routine TB clinical management. X ray imaging cannot discern the type of 577 resistance of tuberculosis as well as characterize the amount of pathogen in sputum, which only 578 microbiological methods can provide. These approaches assist clinicians with a more complete 579 understanding of the case and understanding their relationship is important. CXR is relatively 580 less expensive than other imaging modalities such as CT permitting its wider use especially in 581 LMIC that may face challenges with infrastructure cost to support routine CT use. Using CXRs, 582 radiologists can report on a variety of observations that determine lung biomarker status such as 583 overall abnormal volume of the lungs, presence of cavity, and presence of nodule, which the TB 584 for use under a CC0 license. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 22, 2022. ;

Global Tuberculosis Report 2020 -Reflections on the Global TB 683 burden, treatment and prevention efforts

Impact of the SARS-CoV-2 epidemic on tuberculosis treatment 685 outcome in Northern Italy

Worldwide Effects of Coronavirus Disease Pandemic on 687 Tuberculosis Services

The epidemiology, pathogenesis, transmission, diagnosis, and 689 management of multidrug-resistant, extensively drug-resistant, and incurable 690 tuberculosis

Drug-resistant TB: deadly, 693 costly and in need of a vaccine

Sputum smear microscopy in tuberculosis: is it still relevant?

Time to culture positivity and 697 sputum smear microscopy during tuberculosis therapy

Role of 2-month sputum smears 699 in predicting culture conversion in pulmonary tuberculosis

The challenges of implementing low-dose computed tomography 701 for lung cancer screening in low-and middle-income countries

The long and winding road of 704 chest radiography for tuberculosis detection

Radiographic improvement and its predictors in patients with 706 pulmonary tuberculosis

Chest 708 X ray score (Timika score): an useful adjunct to predict treatment outcome in 709 tuberculosis

A simple, valid, numerical score for grading chest x-ray severity 711 in adult smear-positive pulmonary tuberculosis

Anonymous (2020) WHO consolidated guidelines on tuberculosis: Module 4: Treatment 713 -Drug-resistant tuberculosis treatment, WHO Guidelines Approved by the Guidelines 714 Review Committee

mlr3: A modern object-oriented machine learning framework in R. 716

Body mass index and incidence of tuberculosis

A consistent log-linear 720 relationship between tuberculosis incidence and body mass index

the Timika Score for prediction start with Timika in the pipeline name. Each pipeline shows all 519 steps used in the pipeline ending with the machine learning algorithm used and are ordered by 520 classif.mcc. 521 522 3  1  2  8  6  3  8  9  0  .  6  9  3  3  3  3  3  0  .  6  2  7  9  0  6  9  8   t  i  m  i  k  a  .  n  u  m  _  s  c  a  l  e  .  c  l  a  s  s  i  f  .  n  n  e  t  0  .  7  1  0  5  4  2  6  0  .  3  1  1  8  4  1  2  0  .  7  3  3  3  3  3  3  0  .  5  8  1  3  9  5  3 for temporal analysis of changes in Timika Score over time, the temporal_analysis column 764 provides a filter equal to "yes" to select only those sets of images. 765